Results 161 to 170 of about 56,872 (264)

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Gas Endeavour: An Innovative Equipment for Estimating Methane Kinetics During <i>In Vitro</i> Rumen Fermentation. [PDF]

Animals (Basel)
Iqbal R, Arango S, Tagliapietra F, Bailoni L.   +3 more
europepmc   +1 more source

Is loneliness the HPV of general practice's burnout cancer? [PDF]

Br J Gen Pract
Whitehead IO.
europepmc   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Establishing accountability and promoting rights: the WHO QualityRights contribution to mental health, recovery and community inclusion. [PDF]

BJPsych Open
Eaton J.
europepmc   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Surgery of the lateral skull base: a 50-year endeavour

Acta Otorhinolaryngologica Italica, 2019
E. Zanoletti, A. Mazzoni, A. Martini, R. V. Abbritti, R. Albertini, E. Alexandre, V. Baro, S. Bartolini, D. Bernardeschi, R. Bivona, M. Bonali, I. Borghesi, D. Borsetto, R. Bovo, M. Breun, F. Calbucci, M. L. Carlson, A. Caruso, P. Cayé-Thomasen, D. Cazzador, P. -O. Champagne, R. Colangeli, G. Conte, D. D’Avella, G. Danesi, L. Deantonio, L. Denaro, F. Di Berardino, R. Draghi, F. H. Ebner, N. Favaretto, G. Ferri, A. Fioravanti, S. Froelich, A. Giannuzzi, L. Girasoli, B. R. Grossardt, M. Guidi, R. Hagen, S. Hanakita, D. G. Hardy, V. C. Iglesias, S. Jefferies, H. Jia, M. Kalamarides, I. N. Kanaan, M. Krengli, A. Landi, L. Lauda, D. Lepera, S. Lieber, S. L. K. Lloyd, A. Lovato, F. Maccarrone, R. Macfarlane, J. Magnan, L. Magnoni, D. Marchioni, J. P. Marinelli, G. Marioni, V. Mastronardi, C. Matthies, D. A. Moffat, S. Munari, M. Nardone, R. Pareschi, C. Pavone, E. Piccirillo, G. Piras, L. Presutti, G. Restivo, M. Reznitsky, E. Roca, A. Russo, M. Sanna, L. Sartori, M. Scheich, W. Shehata-Dieler, D. Soloperto, F. Sorrentino, O. Sterkers, A. Taibah, M. Tatagiba, G. Tealdo, D. Vlad, H. Wu, D. Zanetti   +86 more
doaj   +1 more source

E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer

Molecular Oncology, EarlyView.
Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov, Shiva Krishna Katkam, Zhefan Wang, Venkateshwar G. Keshamouni   +3 more
wiley   +1 more source

The doctor-patient relationship and informed consent process. [PDF]

Singapore Med J
Ang TL, Teo EK.
europepmc   +1 more source